一品红：子公司获得草酸艾司西酞普兰滴剂注册证书

Core Viewpoint - Yipinhong Pharmaceutical's subsidiary has received approval for the registration of Escitalopram Oxalate Drops, which are indicated for the treatment of depression and panic disorder with or without agoraphobia [1] Company Summary - Yipinhong Pharmaceutical's wholly-owned subsidiary has been granted a drug registration certificate by the National Medical Products Administration for Escitalopram Oxalate Drops [1] - The approved product is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Industry Summary - According to data from Minet, the sales scale of Escitalopram in urban and county-level public hospitals in China is projected to be approximately 1.88 billion yuan in 2024 [1]